Collegium Pharmaceutical, Inc. Cost of Revenue
Collegium Pharmaceutical, Inc. (COLL) reported Cost of Revenue of $89.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $89.59M, a 12.52% increase year-over-year.
- Collegium Pharmaceutical, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $76.27M, a 5.17% decline year-over-year.
- Collegium Pharmaceutical, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $77.07M, a 7.88% decline year-over-year.
- Collegium Pharmaceutical, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $80.19M, a 28.29% increase year-over-year.
- Collegium Pharmaceutical, Inc. cost of goods and services sold for fiscal 2025 was $317.31M, a 24.87% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. cost of goods and services sold for fiscal 2024 was $254.10M, a 5.61% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. cost of goods and services sold for fiscal 2023 was $240.60M, a 5.44% decline from fiscal 2022.
- Collegium Pharmaceutical, Inc. cost of goods and services sold for fiscal 2022 was $254.44M, a 101.54% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.59M 10-Q · filed 2026-08-06 | $165.86M 10-Q · filed 2026-08-06 | $242.93M derived: sum of 3 quarters · filed 2026-08-06 | $323.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $76.27M 10-Q · filed 2026-05-07 | $153.34M derived: sum of 2 quarters · filed 2026-05-07 | $233.53M derived: sum of 3 quarters · filed 2026-05-07 | $313.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $77.07M 10-K · filed 2026-02-26 | $157.26M derived: sum of 2 quarters · filed 2026-02-26 | $236.88M derived: sum of 3 quarters · filed 2026-08-06 | $317.31M 10-K · filed 2026-02-26 |
| 2025-09-30 | $80.19M 10-K · filed 2026-02-26 | $159.81M derived: sum of 2 quarters · filed 2026-08-06 | $240.24M 10-Q · filed 2025-11-06 | $323.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $79.62M 10-Q · filed 2026-08-06 | $160.05M 10-Q · filed 2026-08-06 | $243.71M derived: sum of 3 quarters · filed 2026-08-06 | $306.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $80.43M 10-Q · filed 2026-05-07 | $164.09M derived: sum of 2 quarters · filed 2026-05-07 | $226.60M derived: sum of 3 quarters · filed 2026-05-07 | $281.07M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $83.66M 10-K · filed 2026-02-26 | $146.17M derived: sum of 2 quarters · filed 2026-02-26 | $200.64M derived: sum of 3 quarters · filed 2026-02-26 | $254.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $62.51M 10-K · filed 2026-02-26 | $116.98M derived: sum of 2 quarters · filed 2026-02-26 | $170.44M 10-Q · filed 2025-11-06 | $225.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $54.47M 10-K · filed 2026-02-26 | $107.94M 10-Q · filed 2025-08-07 | $163.05M derived: sum of 3 quarters · filed 2026-02-26 | $219.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $53.47M 10-K · filed 2026-02-26 | $108.58M derived: sum of 2 quarters · filed 2026-02-26 | $164.98M derived: sum of 3 quarters · filed 2026-02-26 | $226.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $55.12M 10-K · filed 2025-02-27 | $111.51M derived: sum of 2 quarters · filed 2025-02-27 | $173.23M derived: sum of 3 quarters · filed 2025-02-27 | $240.60M 10-K · filed 2026-02-26 |
| 2023-09-30 | $56.40M 10-K · filed 2025-02-27 | $118.12M derived: sum of 2 quarters · filed 2025-02-27 | $185.48M 10-Q · filed 2024-11-07 | $265.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $61.72M 10-K · filed 2025-02-27 | $129.09M 10-Q · filed 2024-08-08 | $208.92M derived: sum of 3 quarters · filed 2025-02-27 | $277.09M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $67.36M 10-K · filed 2025-02-27 | $147.20M derived: sum of 2 quarters · filed 2025-02-27 | $215.37M derived: sum of 3 quarters · filed 2025-02-27 | $286.56M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $79.83M 10-K · filed 2024-02-22 | $148.00M derived: sum of 2 quarters · filed 2024-02-22 | $219.19M derived: sum of 3 quarters · filed 2024-02-22 | $254.44M 10-K · filed 2025-02-27 |
| 2022-09-30 | $68.17M 10-K · filed 2024-02-22 | $139.36M derived: sum of 2 quarters · filed 2024-02-22 | $174.61M 10-Q · filed 2023-11-07 | $203.31M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $71.19M 10-K · filed 2024-02-22 | $106.44M 10-Q · filed 2023-08-03 | $135.13M derived: sum of 3 quarters · filed 2024-02-22 | $167.87M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $35.26M 10-K · filed 2024-02-22 | $63.95M derived: sum of 2 quarters · filed 2024-02-22 | $96.68M derived: sum of 3 quarters · filed 2024-02-22 | $129.38M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $28.70M 10-K · filed 2023-02-23 | $61.42M derived: sum of 2 quarters · filed 2023-02-23 | $94.13M derived: sum of 3 quarters · filed 2023-02-23 | $126.25M 10-K · filed 2024-02-22 |
| 2021-09-30 | $32.73M 10-K · filed 2023-02-23 | $65.43M derived: sum of 2 quarters · filed 2023-02-23 | $97.56M 10-Q · filed 2022-11-03 | $129.53M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $32.70M 10-K · filed 2023-02-23 | $64.83M 10-Q · filed 2022-08-04 | $96.81M derived: sum of 3 quarters · filed 2023-02-23 | $127.79M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $32.12M 10-K · filed 2023-02-23 | $64.10M derived: sum of 2 quarters · filed 2023-02-23 | $95.08M derived: sum of 3 quarters · filed 2023-02-23 | $124.78M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $31.98M 10-K · filed 2022-02-24 | $62.96M derived: sum of 2 quarters · filed 2022-02-24 | $92.66M derived: sum of 3 quarters · filed 2022-02-24 | $130.18M 10-K · filed 2023-02-23 |
| 2020-09-30 | $30.98M 10-K · filed 2022-02-24 | $60.68M derived: sum of 2 quarters · filed 2022-02-24 | $98.20M 10-Q · filed 2021-11-04 | $147.29M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $29.69M 10-K · filed 2022-02-24 | $67.22M 10-Q · filed 2021-08-05 | $116.31M derived: sum of 3 quarters · filed 2022-02-24 | $163.06M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $37.52M 10-K · filed 2022-02-24 | $86.61M derived: sum of 2 quarters · filed 2022-02-24 | $133.37M derived: sum of 3 quarters · filed 2022-02-24 | $182.02M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $49.09M 10-K · filed 2021-02-25 | $95.84M derived: sum of 2 quarters · filed 2021-02-25 | $144.50M derived: sum of 3 quarters · filed 2021-02-25 | $193.66M 10-K · filed 2022-02-24 |
| 2019-09-30 | $46.75M 10-K · filed 2021-02-25 | $95.41M derived: sum of 2 quarters · filed 2021-02-25 | $144.57M 10-Q · filed 2020-11-05 | $174.30M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $48.65M 10-K · filed 2021-02-25 | $97.82M 10-Q · filed 2020-08-05 | $127.54M derived: sum of 3 quarters · filed 2021-02-25 | $173.55M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $49.16M 10-K · filed 2021-02-25 | $78.89M derived: sum of 2 quarters · filed 2021-02-25 | $124.90M derived: sum of 3 quarters · filed 2021-02-25 | $171.74M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $29.73M 10-K · filed 2020-02-27 | $75.73M derived: sum of 2 quarters · filed 2020-02-27 | $122.57M derived: sum of 3 quarters · filed 2020-02-27 | $165.68M 10-K · filed 2021-02-25 |
| 2018-09-30 | $46.01M 10-K · filed 2020-02-27 | $92.84M derived: sum of 2 quarters · filed 2020-02-27 | $135.95M 10-Q · filed 2019-11-06 | $137.04M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $46.84M 10-K · filed 2020-02-27 | $89.94M 10-Q · filed 2019-08-07 | $91.04M derived: sum of 3 quarters · filed 2020-02-27 | $91.59M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $43.11M 10-K · filed 2020-02-27 | $44.20M derived: sum of 2 quarters · filed 2020-02-27 | $44.75M derived: sum of 3 quarters · filed 2020-02-27 | $45.33M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $1.09M 10-K · filed 2019-02-27 | $1.65M derived: sum of 2 quarters · filed 2019-02-27 | $2.22M derived: sum of 3 quarters · filed 2019-02-27 | $2.60M 10-K · filed 2020-02-27 |
| 2017-09-30 | $553.00K 10-K · filed 2019-02-27 | $1.13M derived: sum of 2 quarters · filed 2019-02-27 | $1.50M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $577.00K 10-K · filed 2019-02-27 | $948.00K 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $371.00K 10-K · filed 2019-02-27 | |||
| 2016-12-31 | $213.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |